Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
Fregona V, Bayet M, Bouttier M, Largeaud L, Hamelle C, Jamrog LA, Prade N, Lagarde S, Hebrard S, Luquet I, Mansat-De Mas V, Nolla M, Pasquet M, Didier C, Khamlichi AA, Broccardo C, Delabesse É, Mancini SJC, Gerby B. Fregona V, et al. Among authors: delabesse e. J Exp Med. 2024 Jan 1;221(1):e20230279. doi: 10.1084/jem.20230279. Epub 2023 Nov 6. J Exp Med. 2024. PMID: 37930337 Free PMC article.
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.
Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachée-Chardin M, Mansat-De Mas V, Corre J, Récher C, Plat G, Bachelerie F, Donadieu J, Delabesse E. Pasquet M, et al. Among authors: delabesse e. Blood. 2013 Jan 31;121(5):822-9. doi: 10.1182/blood-2012-08-447367. Epub 2012 Dec 6. Blood. 2013. PMID: 23223431 Free PMC article. Clinical Trial.
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, Dobbelstein S, Dastugue N, Mansat-De Mas V, Delabesse E, Duchayne E, Demur C, Sarry A, Lauwers-Cances V, Laurent G, Attal M, Récher C. Bertoli S, et al. Among authors: delabesse e. Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30. Blood. 2013. PMID: 23365464 Free article.
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S. Bertoli S, et al. Among authors: delabesse e. Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706. Oncotarget. 2015. PMID: 26515730 Free PMC article.
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE. Boutzen H, et al. Among authors: delabesse e. J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7. J Exp Med. 2016. PMID: 26951332 Free PMC article. Clinical Trial.
CHK1 as a therapeutic target to bypass chemoresistance in AML.
David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE, Delabesse E, Cazaux C, Didier C, Récher C, Manenti S, Hoffmann JS. David L, et al. Among authors: delabesse e. Sci Signal. 2016 Sep 13;9(445):ra90. doi: 10.1126/scisignal.aac9704. Sci Signal. 2016. PMID: 27625304 Clinical Trial.
183 results